Statin treatment and hypertrophic scarring after cardiac surgery.
Aged
Atorvastatin
/ therapeutic use
Cardiac Surgical Procedures
/ adverse effects
Cicatrix, Hypertrophic
/ diagnosis
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Male
Retrospective Studies
Surgical Wound
/ complications
Treatment Outcome
Wound Healing
/ drug effects
Journal
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
ISSN: 1524-475X
Titre abrégé: Wound Repair Regen
Pays: United States
ID NLM: 9310939
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
06
2020
revised:
03
09
2020
accepted:
13
10
2020
pubmed:
26
11
2020
medline:
3
11
2021
entrez:
25
11
2020
Statut:
ppublish
Résumé
Wound healing process after surgical procedure plays a crucial role to prevent blood loss and infections. Hypertrophic scars might occur after surgery and are generally associated with an inflammatory burden. Cardiac surgery is intrinsically related to a strong systemic inflammatory state that might favor hypertrophic scarring. Besides lipid-lowering effects, statins are known for their pleiotropic and anti-inflammatory activity. The aim of this study was to investigate the impact of statins in the healing process after median sternotomy in patients undergoing cardiac surgery. All patients undergoing major cardiac surgery with median sternotomy and cardiopulmonary bypass, and subsequently evaluated in the outpatient clinic after discharge, were included in this study. A total of 930 Caucasian patients were retrospectively reviewed. At outpatient visit, 276 patients (29.7%) showed the formation of hypertrophic scars. Patients with hypertrophic scars tended to be younger (P = .001) and nonstatin users (P = .001). Logistic regression analysis confirmed the protective role of statins (odds ratio 0.39, 95% confidence interval 0.29-0.53, P = .001), after adjustment for age. A dose-dependent effect was confirmed, showing a more intensive protective effect for higher doses of statins. Statin use might be correlated with reduced hypertrophic scars after cardiac surgery through median sternotomy. A dose-dependent effect has been shown, and statin effect seems to be independent of age in a selected population undergoing surgery with an elevated inflammatory burden. Although further studies are warranted to elucidate the biologic mechanisms, the concept of using statins as anti-scarring agents is novel and should be investigated with tailored studies.
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-133Informations de copyright
© 2020 by the Wound Healing Society.
Références
Chello C, Lusini M, Nenna A, et al. Deep Sternal Wound Infection (DSWI) and mediastinitis after cardiac surgery: current approaches and future trends in prevention and management. Surg Technol Int. 2020;36:212-216.
Nenna A, Nappi F, Dougal J, et al. Sternal wound closure in the current era: the need of a tailored approach. Gen Thorac Cardiovasc Surg. 2019;67(11):907-916.
Berman B, Bieley HC. Keloids. J Am Acad Dermatol. 1995;33(1):117-123.
Butzelaar L, Ulrich MM, Mink van der Molen AB, Niessen FB, Beelen RH. Currently known risk factors for hypertrophic skin scarring: a review. J Plast Reconstr Aesthet Surg. 2016;69(2):163-169.
Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res. 2006;297(10):433-438.
Butzelaar L, Soykan EA, Galindo Garre F, et al. Going into surgery: risk factors for hypertrophic scarring. Wound Repair Regen. 2015;23(4):531-537.
Qian LW, Fourcaudot AB, Yamane K, You T, Chan RK, Leung KP. Exacerbated and prolonged inflammation impairs wound healing and increases scarring. Wound Repair Regen. 2016;24(1):26-34.
Kafka M, Collins V, Kamolz LP, Rappl T, Branski LK, Wurzer P. Evidence of invasive and noninvasive treatment modalities for hypertrophic scars: a systematic review. Wound Repair Regen. 2017;25(1):139-144.
van der Veer WM, Bloemen MC, Ulrich MM, et al. Potential cellular and molecular causes of hypertrophic scar formation. Burns. 2009;35(1):15-29.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Jama. 2004;291(9):1071-1080.
Nischwitz SP, Rauch K, Luze H, et al. Evidence-based therapy in hypertrophic scars-an update of a systematic review. Wound Repair Regen. 2020;28:656-665.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
Sarrazy V, Billet F, Micallef L, Coulomb B, Desmouliere A. Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen. 2011;19(Suppl 1):s10-s15.
Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200(4):500-503.
Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg. 2002;110(1):177-183. discussion 84-6.
Kapoor M, Liu S, Shi-wen X, et al. GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest. 2008;118(10):3279-3290.
Nenna A, Lusini M, Spadaccio C, et al. Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. J Cardiovasc Med (Hagerstown). 2017;18(12):976-982.
Nenna A, Spadaccio C, Lusini M, et al. Preoperative atorvastatin reduces bleeding and blood transfusions in patients undergoing elective isolated aortic valve replacement. Interact Cardiovasc Thorac Surg. 2019;29(1):51-58.
Thompson CM, Sood RF, Honari S, Carrougher GJ, Gibran NS. What score on the Vancouver Scar Scale constitutes a hypertrophic scar? Results from a survey of North American burn-care providers. Burns. 2015;41(7):1442-1448.
Kaartinen IS, Valisuo PO, Bochko V, Alander JT, Kuokkanen HO. How to assess scar hypertrophy-a comparison of subjective scales and Spectrocutometry: a new objective method. Wound Repair Regen. 2011;19(3):316-323.
Hedayatyanfard K, Ziai SA, Niazi F, Habibi I, Habibi B, Moravvej H. Losartan ointment relieves hypertrophic scars and keloid: a pilot study. Wound Repair Regen. 2018;26(4):340-343.
Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol. 2007;25(1):26-32.
Huang C, Liu L, You Z, Du Y, Ogawa R. Managing keloid scars: from radiation therapy to actual and potential drug deliveries. Int Wound J. 2019;16(3):852-859.
Wang M, Chen L, Huang W, et al. Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes. Int J Nanomedicine. 2019;14:1385-1400.
Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80(3):253-260.
Rabello FB, Souza CD, Farina Júnior JA. Update on hypertrophic scar treatment. Clinics (Sao Paulo). 2014;69(8):565-573.
Nabai L, Pourghadiri A, Ghahary A. Hypertrophic scarring: current knowledge of predisposing factors, cellular and molecular mechanisms. J Burn Care Res. 2020;41(1):48-56.
Ko JH, Kim PS, Zhao Y, Hong SJ, Mustoe TA. HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model. Plast Reconstr Surg. 2012;129(2):252e-261e.
Xie P, Dolivo DM, Jia S, et al. Liposome-encapsulated statins reduce hypertrophic scarring through topical application. Wound Repair Regen. 2020;28:460-469.
Mun JH, Kim YM, Kim BS, Kim JH, Kim MB, Ko HC. Simvastatin inhibits transforming growth factor-β1-induced expression of type I collagen, CTGF, and α-SMA in keloid fibroblasts. Wound Repair Regen. 2014;22(1):125-133.
Jia S, Xie P, Hong SJ, Galiano RD, Mustoe TA. Local application of statins significantly reduced hypertrophic scarring in a rabbit ear model. Plastic and Reconstructive Surgery - Global Open. 2017;5(6):e1294.
Schiefelbein D, Goren I, Fisslthaler B, et al. Biphasic regulation of HMG-CoA reductase expression and activity during wound healing and its functional role in the control of keratinocyte angiogenic and proliferative responses. J Biol Chem. 2008;283(22):15479-15490.
Cáceres M, Romero A, Copaja M, Díaz-Araya G, Martínez J, Smith PC. Simvastatin alters fibroblastic cell responses involved in tissue repair. J Periodontal Res. 2011;46(4):456-463.
Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110(2):560-571.
Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg. 2008;61(1):4-17.
Giacinto O, Satriano U, Nenna A, et al. Inflammatory response and endothelial dysfunction following cardiopulmonary bypass: pathophysiology and pharmacological targets. Recent Pat Inflamm Allergy Drug Discov. 2019;13(2):158-173.
Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006;34(3):660-667.